Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

INTRODUCTION: The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme. The current post-hoc exploratory subgroup analyses...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Pratley, Richard E., Crowley, Matthew J., Gislum, Mette, Hertz, Christin L., Jensen, Thomas B., Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7994454/
https://ncbi.nlm.nih.gov/pubmed/33660198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00994-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars